Stay updated with breaking news from Conley Chee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Syros Pharmaceuticals (SYRS), a company focused on hematologic malignancies, said on Monday that it is cutting around 35 percent of its staff as part of its efforts to focus on late-stage development of tamibarotene in MDS and AML and ongoing pre-launch activities.
Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonian, who...
By Oyin Adeoyin Syros Pharmaceuticals shares fell after the company cut more than one- third of its staff and said its chief executive will resign. The stock...
Operator: Good morning, and welcome to Syros Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. [Operator Instructions].
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical ProgramsSyros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal DataNow Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023Syros to Host Conference Call at 8:30 AM ET Today...